APTA Therapeutics Receives Notice of Allowance for Key Patent in the United States and Japan

APTA Therapeutics, today announced that it has received notices of allowance for a key patent application in both the United States and Japan, marking a significant milestone in the company’s intellectual property strategy.

“This is a major step forward for APTA,” said Dr. Oliver von Stein, CEO. “It further strengthens the company’s significant IP portfolio to support the development of innovative therapies in areas of high unmet need. The patent provides broad protection for the use of rovunaptabin (formally BC 007) in coronaviridae infections and related post‑viral disease sequelae, including Long COVID and chronic fatigue syndrome.”